The First Urine HPV Detection Product Will Be Listed On The "Home Screening" As A New Trend In Cancer Screening.

In October 28th, Nuo Hui health is an early screening product for colorectal cancer, which is more convenient for home cancer screening. Nuo Hui health CEO Zhu Yeqing told the twenty-first Century economic news reporter that Nuo Hui health focused on developing early screening technology for colorectal cancer and lung cancer, and launched a series of early screening products for colorectal cancer.

Zhu Yeqing believes that home screening will become the trend of cancer screening. No pain, no invasion, and can be sampled at home. Products with convenient flow and accurate results are helpful for early detection, early diagnosis and early treatment of cancer. Not long ago, Nuo Hui health also released the latest blockbuster scientific research achievement "palace certification", the corresponding landing products are in the reporting stage, is expected to be officially listed in the next 1-2 years, this is the world's first urine HPV detection products. This is also a more convenient and convenient method for home inspection.

Professor Wei Lihui, honorary director of the Department of Obstetrics and Gynecology of Peking University People's Hospital and Professor Emeritus of the Department of Obstetrics and Gynecology, Peking University, pointed out to the twenty-first Century economic report that cervical cancer screening is still dead. From the published papers of Nuo Hui health, the sensitivity of urine HPV detection is higher than cytology, and it is easy to get materials. This is a trend and there is also a HPV detection pathway in the future. However, Wei Lihui specifically emphasized that the clinical results should be specific.

According to Zhao Ping, director of the China Cancer Foundation, early screening for cancer at home can provide a lot of convenience and help early detection, early diagnosis and early treatment of cancer, but more importantly, people need to know the importance of early diagnosis and are willing to pay for their own health.

Urine screening for cervical cancer

"99.7% of cervical cancer is caused by HPV virus infection, but the vast majority of HPV infection will automatically recover within two years, which is different from the virus commonly seen. Only a small part will go through ten to thirty years, gradually evolving from the normal cell to the 123 stage of canceration, and become cervical cancer. Dr. Chen Yiyou, chief scientist of Nuo Hui health.

Public data showed that in 2012, 98 thousand and 900 new cases of cervical cancer and 305 thousand deaths occurred in China. By 2015, the number of new cases of cervical cancer in China rose to 106 thousand and 430, and the death rate rose to 477 thousand.

In fact, the history of screening is very long, but the incidence of cervical cancer is still increasing from the above data. In this regard, Wei Lihui pointed out that an important reason why the incidence rate is not down is the mass consciousness. Despite repeated propaganda, China's coverage is less than 40%, and the eastern coastal areas may be a little higher. "The other is the screening method. The original screening methods always have missed diagnosis and trauma, and to a certain extent, there will be bottlenecks. Now we need more accurate screening methods."

As early as 2014, there were reports that scientists identified 14 papillomavirus DNA sequences that might help them diagnose HPV. The overall sensitivity of urine test for HPV positive results was 87% and negative result was 94%. Compared with Pap smear, the sensitivity of urine test to confirm the positive high-risk HPV strain was 73%, and 98% when the negative result was confirmed.

In Wei Lihui's opinion, urine tests provide an alternative for women to test HPV. Chen Yiyou introduced that Nuo Hui's healthy products were mainly detected by the multiple fluorescence PCR of urine samples, and tested for the 14 recognized high-risk HPV subtypes. From the direction of screening, to help users prevent the occurrence of cervical cancer.

According to the introduction, nuohui's health research and development of the new technology has many advantages in convenience, for example, it can be sampled in any place including hospitals, families and so on. With the sample stabilization technology, urine can be stable for two weeks at room temperature, urine samples can be fully automated, and the detection results are objective and repeatable. Another important advantage is that it is completely painless and noninvasive, avoiding the embarrassment and embarrassment of many women.

Early screening of high incidence cancer species

Whether it is the early screening products for rectal cancer and lung cancer or the upcoming HPV screening products, Nuo Hui health is the scene of home screening.

Zhu Yeqing told the twenty-first Century economic news reporter that this is related to Nuo Hui's overall health strategy, and that the early screening of home will become the trend of early screening of tumors.

"First of all, China's medical resources are scarce, and it is unrealistic to cover all the people. Secondly, China's consumption level is still very high. It is difficult to cover all people with a technology and products. Thirdly, the most important thing for screening is compliance. Now people are reluctant to do it because the hospital is too troublesome. In the end, relatively speaking, the cost of going to hospital is relatively high." Zhu Yeqing believes that in order to achieve the popularity of early cancer screening, promoting home screening is inevitable.

In Zhao Ping's view, Nuo Hui's early screening products such as colorectal cancer and lung cancer can provide a lot of convenience, but also help early detection, early diagnosis and early treatment of cancer.

The action plan for healthy China (2019-2030) emphasizes the importance of actively promoting cancer prevention, promoting early screening, early diagnosis and early treatment, reducing the incidence and mortality of cancer, improving the quality of life of patients, and strengthening scientific and technological research in cancer prevention and treatment. By 2022 and 2030, the overall 5 year survival rate of cancer was not less than 43.3% and 46.6% respectively.

Early diagnosis and early treatment are internationally recognized as the most effective means of fighting cancer. The 2017 edition of the annual report on cancer in the United States shows that in the past 20 years, the mortality rate of cancer in the United States has dropped by 25%, that is, more than 2 million 100 thousand people have died from cancer, and the 5 year survival rate of cancer patients has reached 64%.

In July 2018, the American Cancer Center published the next 10 years' first class cancer resistance plan, called "2030 blueprint for cancer prevention and mortality decline". It analyzed in detail the change of cancer mortality in the first 1930-2010 years and 80 years after the first three years of cancer in the United States, and the cancer screening was emphasized again.

However, Zhu Yeqing pointed out that there are still difficulties in pushing home early screening. First of all, it is authoritative. It needs clinical value, including the ability of technology and clinical trials, especially when large scale clinical trials are taken, whether the products can have higher sensitivity and specificity, and the data processing capability. This supports the accuracy and effectiveness of follow-up links, and at the same time, products are also commercialized, which is also the foundation for maintaining the normal operation of an enterprise.

At the same time, Zhao Ping also pointed out that more importantly, people need to know the importance of early diagnosis and are willing to pay for their health voluntarily. "The national medical insurance fund is limited, there are many needs to support, so in the early screening of cancer, it is more feasible that the state, society and individuals share the burden."

Zhu Yeqing also agrees with the above view. He believes that there is still a long way to go before the early screening of cancer is included in the national health insurance program for medical insurance reimbursement. In the current situation in China, health management and cancer screening need more action, and the users will pay the bill by themselves, which can be paid by commercial insurance in the future.